Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,630 total articles
MiNK Therapeutics announced Phase II trial results showing their cell therapy agenT-797, combined with botensilimab and balstilimab, achieved a 77% disease control rate and durable survival beyond 20 months in patients with advanced PD-1 refractory gastroesophageal cancer. An induction treatment strategy yielded significant improvements in progress…
Zymeworks Inc. disclosed multiple new preclinical and clinical data sets at the AACR 2026 meeting, highlighting its advanced antibody-drug conjugate (ADC) programs targeting difficult-to-treat cancers, including RAS-mutated tumors. Key presentations showcased efficacy, tumor-selective delivery, and favorable tolerability of novel ADCs such as ZW191…
Atour Lifestyle Holdings Limited, a leading Chinese lifestyle group operating in hospitality and retail sectors, announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025. The report is accessible on the company's investor website and the SEC's website, with hard copies available upon request.
Zentalis Pharmaceuticals announced encouraging preclinical results for its WEE1 inhibitor, azenosertib, showing efficacy in triple-negative breast cancer (TNBC) models resistant to antibody-drug conjugates. Additionally, real-world data reveal poor outcomes for Cyclin E1-positive ovarian cancer patients under current treatments, emphasizing the unm…
Surgery Partners, Inc., a leading outpatient surgical services provider, announced that it will release its first quarter 2026 earnings before market open on May 5, 2026, followed by a conference call the same day. The company provides high-quality, cost-effective surgical and ancillary care through over 200 locations in 30 states.
Akamai Technologies announced that MediaMelon, a streaming intelligence company, has joined its Qualified Compute Partner Program as an Independent Software Vendor. MediaMelon's SmartSight platform, providing real-time video streaming analytics and AI-powered insights, will now be integrated and scaled on Akamai's globally distributed cloud. This p…
KANZHUN LIMITED, trading as BOSS Zhipin, announced continued share repurchases in 2026 totaling over RMB896 million, demonstrating its strong commitment to enhancing shareholder returns through its ongoing buyback program.
Essent Group Ltd., a Bermuda-based holding company providing private mortgage insurance, reinsurance, and title insurance services, announced it will hold a conference call to discuss its Q1 2026 financial results on May 8, 2026. The results will be released before market open that day, with the call accessible both via webcast and phone.
TTEC Holdings, Inc., a global consulting, technology, and managed services company, announced it will release its first quarter 2026 earnings results on May 7, 2026, followed by a webcasted investor conference call on May 8, 2026. The earnings release and webcast provide investors an opportunity to assess the company's financial performance and fut…
CAMP4 Therapeutics Corporation reported that its Compensation Committee granted inducement stock options totaling 43,000 shares to three newly hired employees. These options have a ten-year term, an exercise price equal to the closing stock price on the grant date ($4.59), and vest over four years, designed to incentivize talent acquisition and ret…
Talen Energy Corporation has priced $4 billion in senior notes due 2031 and 2033 to finance its acquisition of 2,451 MW of power generation capacity and redeem existing higher-coupon debt. The move supports the company's expansion with additional fossil and nuclear assets, strengthening its position in the U.S. power generation market.
BioXcel Therapeutics announced a virtual event focused on their commercial launch plan for IGALMI®, targeting the treatment of acute agitation associated with bipolar disorder and schizophrenia in the at-home setting, ahead of the November 14 PDUFA date. Market assessment highlights a significant opportunity with up to 86 million annual addressable…
Pyxis Oncology announced new preclinical data demonstrating that its lead candidate, micvotabart pelidotin (MICVO), a novel antibody-drug conjugate, shows significant anti-tumor activity as monotherapy and synergistic effects when combined with anti-PD-1 therapy in a head and neck squamous cell carcinoma (HNSCC) model. These findings support ongoin…
Applied Optoelectronics, Inc. is expanding its Houston-area facilities by adding two adjacent buildings in Pearland, Texas, increasing its manufacturing capacity by about 388,000 square feet. This move supports the company’s ambitious 2027 capacity targets and positions AOI to scale production of high-speed optical transceivers and laser fabricatio…
ORIC Pharmaceuticals announced the presentation of multiple preclinical data posters at the 2026 AACR Annual Meeting demonstrating the potential of their drug candidate rinzimetostat, an allosteric PRC2 inhibitor, to treat prostate cancer, including treatment-resistant forms. The data indicates strong antitumor activity across prostate cancer model…
Intchains Group Limited reports active staking of over 8,000 ETH on multiple platforms to optimize returns from its treasury assets, while undertaking a strategic transformation by embedding AI-enabled tools across its operations to enhance efficiency, streamline costs, and drive innovation in its altcoin mining and Web3 infrastructure services bus…
4D Molecular Therapeutics announced equity inducement grants of 67,600 Restricted Stock Units to five new non-executive employees as part of its 2025 Employment Inducement Award Plan. The grants aim to attract talent to support the company’s development of late-stage gene therapies targeting retinal diseases and cystic fibrosis.
USA Rare Earth has appointed Chaitan Kansal as Chief Commercial Officer in a new role to lead global commercial strategy, accelerate customer engagement, and secure long-term offtake agreements. This comes as the company moves from development to active production with recent milestones including commissioning of commercial magnet production and st…
QuasarEdge Acquisition Corporation announced that the underwriters of its recent IPO exercised their over-allotment option to purchase an additional 1.5 million units at $10 per unit, raising total units sold to 11.5 million. The units trade on the NYSE under ticker "QRED U" and consist of one ordinary share plus fractional rights, with separate tr…
Vera Bradley, Inc. announced the termination of its existing shareholder rights plan effective April 17, 2026, earlier than the originally scheduled October 11, 2026 expiration. The Board cites a reassessment of control risks through market accumulations and believes the plan is no longer necessary at this time. The company remains committed to pro…
ALX Oncology Holdings Inc., a clinical-stage biotechnology company, announced that its Compensation Committee approved an inducement stock option grant of 800,000 shares to Jeff Knight, the newly appointed Chief Development and Operating Officer, as per Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing st…
Zhihu Inc., a leading online content community in China, has filed its annual report for the fiscal year ended December 31, 2025, on Form 20-F with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible on the company’s investor relations website. Zhihu offers free hard copies to…
Revolution Medicines, a Nasdaq-listed late-stage clinical oncology company specializing in RAS-addicted cancer therapies, completed concurrent upsized public offerings of common stock and convertible senior notes totaling approximately $2.2 billion. The net proceeds will be utilized to support research and development, potential commercialization, …
Hingham Institution for Savings reported first quarter 2026 earnings showing a 60.2% decrease in GAAP net income per share compared to last year, primarily due to a net loss on equity securities. However, Core net income, excluding equity securities gains/losses, rose 72.3%. Total assets grew slightly to $4.55 billion with retail and commercial dep…
Olema Oncology announced compelling preclinical data for its breast cancer therapies palazestrant and OP-3136 at the 2026 AACR Annual Meeting. Palazestrant, a complete estrogen receptor antagonist and degrader, demonstrated robust anti-tumor activity by recruiting corepressor NCoR1 to fully block estrogen receptor activity. Combined with OP-3136, a…
